Viro channel is an interactive platform for physicians and allied healthcare professionals with an interest in virology

We offer different educational programs, articles and conference reviews pertaining clinically relevant advances and developments in the science and practice of virology medicine.

Our aim is to enable  peer-to-peer exchanges and help healthcare professionals stay current in their practice.

PROGRAMS

POST WORLD AIDS 2016

POST WORLD AIDS 2016

2 December 2016

, , , ,

Residual Immune Dysregulation in the Age of New Antiretroviral Therapies

Residual Immune Dysregulation in the Age of New Antiretroviral Therapies

11 October 2016

,

Hepatitis C Treatment: The French Experience

Hepatitis C Treatment: The French Experience

16 June 2016

Simplifying antiretroviral treatment

Simplifying antiretroviral treatment

29 April 2016

, ,

HIV: Beyond Undetectability

HIV: Beyond Undetectability

14 April 2016

, , ,

Management of HIV/HCV co-infection

Management of HIV/HCV co-infection

26 January 2016

, , ,

Characterization of HIV reservoirs

Characterization of HIV reservoirs

24 November 2015

, ,

Personalized Treatments in HIV Prevention and Care: What Can We Do in 2015 After CROI?

Personalized Treatments in HIV Prevention and Care: What Can We Do in 2015 After CROI?

24 August 2015

, , , , , ,

HIV Single-tablet Regimens – The Future is Now

HIV Single-tablet Regimens – The Future is Now

10 April 2015

,

I-score: Introducing the patient’s perspective in the evaluation of ART

I-score: Introducing the patient’s perspective in the evaluation of ART

11 December 2014

,

The ART of giving complex patients the tools of medication adherence

The ART of giving complex patients the tools of medication adherence

4 November 2014

, ,

Optimal Use of Integrase Inhibitors in The Treatment of HIV

Optimal Use of Integrase Inhibitors in The Treatment of HIV

12 August 2014

, , , ,

The Evolution of the Standards of Care: The Changing Face of HIV Treatment

The Evolution of the Standards of Care: The Changing Face of HIV Treatment

4 June 2014

, ,

HIV Prevention: Non-Professional Post-Exposure Prophylaxis (PEP)

HIV Prevention: Non-Professional Post-Exposure Prophylaxis (PEP)

16 May 2014

, ,

Antiretroviral Therapy in HIV/HCV Coinfection: Which Role Do Integrase Inhibitors Play?

Antiretroviral Therapy in HIV/HCV Coinfection: Which Role Do Integrase Inhibitors Play?

5 May 2014

, , ,

Hepatitis C

Hepatitis C

1 April 2014

,

HIV-Associated Enteropathy

HIV-Associated Enteropathy

30 March 2014

,

Managing Osteoporosis: Emphasis on Patients with HIV

Managing Osteoporosis: Emphasis on Patients with HIV

20 December 2013

, , ,

ARV therapy: From Our Roots Comes Our Growth

ARV therapy: From Our Roots Comes Our Growth

27 November 2013

, , ,

Innovative Strategies for the Management of HIV Infection

Innovative Strategies for the Management of HIV Infection

12 September 2013

, ,

HIV and Aging

HIV and Aging

28 June 2013

, ,

Antiretroviral Strategies and the Eradication of HIV

Antiretroviral Strategies and the Eradication of HIV

27 June 2013

, , , ,

HIV and Renal Health

HIV and Renal Health

13 June 2013

, ,

Switching HIV Regimens: When, Why, and to What

Switching HIV Regimens: When, Why, and to What

28 July 2012

, , ,

Recent Updates in Treating Special Populations Living With HIV

Recent Updates in Treating Special Populations Living With HIV

27 July 2012

, , ,

The Role of Single Tablet Regimens (STR) & Perspectives on the Future Shape of HIV Treatment & Care

The Role of Single Tablet Regimens (STR) & Perspectives on the Future Shape of HIV Treatment & Care

8 March 2012

, , ,

Debating The Merits of Monotherapy For HIV

Debating The Merits of Monotherapy For HIV

7 March 2012

, , ,

Nuc-Sparing Regimens & Aging with HIV

Nuc-Sparing Regimens & Aging with HIV

4 December 2011

, ,

Expert Review 2011: EACS, HIV and Aging, AASLD (Liver Meeting)

Expert Review 2011: EACS, HIV and Aging, AASLD (Liver Meeting)

30 October 2011

  • Research: PEP Adherence and Efficacy
    Research: PEP Adherence and Efficacy in a Major North American Cohort: PEP regimen was associated with treatment adherence. One month PEP is an effective preventive measure to avoid HIV infection.
  • Patient-reported outcomes and single-tablet regimens
    Study : 48-week treatment with RPV/FTC/TDF or EFV/FTC/TDF was associated with high adherence, high treatment satisfaction, and improved quality of life. TEAE related discontinuations and patient-reported symptoms indicate that RPV/FTC/TDF may be somewhat better tolerated than EFV/FTC/TDF.
  • Statue of the Tired Man - HIV and fatigue
    The most common causes of fatigue in people living with HIV are non-HIV-related causes, which can be treated.

Scientific Committee

The scientific committee’s main role is to suggest themes of publishing and express opinions favorable or unfavorable about the medical content written by our editorial team. They may propose to add, modify, or remove content to ensure ethical integrity. The committee members act independently; their opinions are advisory in nature.
Réjean Thomas, MD, DHC

Réjean Thomas, MD, DHC

Editor-in-chief

CEO | Founder
Clinique médicale l’Actuel: Centre of Excellence HIV – STI – Hepatitis
Affiliated with Centre hospitalier de l’Université de Montréal (CHUM)
Québec, Canada

Bertrand Lebouché, MD, PhD

Bertrand Lebouché, MD, PhD

Scientific Director

Assistant Professor
McGill University Health Centre (MUHC)
Montréal, Québec, Canada

José Arribas, MD

José Arribas, MD

Member

Associate Professor
Autonoma University School of Medicine
Research Director
HIV Unit – La Paz Hospital
Madrid, Spain

Pedro Cahn, MD, PhD

Pedro Cahn, MD, PhD

Member

Chief
Infectious Disease Unit
Juan A Fernandez Hospital
Assistant Professor
Infectious Diseases
Buenos Aires, UMS, Argentina

Christine Katlama, MD

Christine Katlama, MD

Member

Department of Infectious and Tropical Diseases
Hôpital Pitié-Salpêtrière
Paris, France

Mark R. Nelson, MA, MBBS, FRCP

Mark R. Nelson, MA, MBBS, FRCP

Member

Consultant Physician
Chelsea & Westminster Hospital
London, United Kingdom

Jean-Michel Pawtlotsky, MD, PhD

Jean-Michel Pawtlotsky, MD, PhD

Member

Director
Department of virology
Hôpitaux universitaires Henri Mondor
Créteil, France

Mark Wainberg, PhD

Mark Wainberg, PhD

Member

Director
McGill AIDS Centre
Professor
Medicine, Microbiology and Immunology
McGill University
Montréal, Québec, Canada